Validating New NIH Clinical Tools in Parkinson's Disease with/without Depressio

描述(由申请人提供)：本申请涉及广泛的挑战领域(05)比较有效性研究和特定挑战主题，05-NS-103：在患有神经疾病的人群中验证NIH的新临床工具。帕金森氏病(PD)和抑郁症的临床影响已被广泛认识，并具有相当大的临床意义，但人们对它们在生活质量和认知结果方面的独特作用和复杂相互作用知之甚少。因此，对帕金森病患者的生活质量和神经认知功能的测量，特别是在合并抑郁症的情况下，可能具有预后意义。标准评估工具已被用于评估帕金森病和抑郁症的生活质量和神经认知影响，但它们的使用受到较差的心理测量学特性的限制，更重要的是，管理时间较长。为了克服这些限制，NIH开发了两个重要的工具，与健康相关的生活质量(Neuro-QOL)测量，以及NIH神经和行为功能评估工具箱(NIH工具箱)。然而，帕金森病患者的神经生活质量和NIH工具箱尚未标准化。这项验证新的NIH临床工具治疗帕金森氏症伴/不伴抑郁的研究将在160名帕金森病患者中利用Neuro-QOL和NIH工具箱(目标1)，并将辨别可归因于帕金森氏症或抑郁症状的影响(目标2)。这一拟议的项目将推进NINDS的使命，即开发新的标准化测试，作为NIH神经科学蓝图的一部分，特别是在帕金森氏病和伴发抑郁症患者的生活质量和神经认知测量方面。此外，该项目将满足《美国复苏和再投资法案》的目标，即1)基础设施投资--通过开展多学科研究，为当前和未来的努力创建一个协同的心理测量测试开发平台，以及2)保留和创造就业机会--雇用现有教师、早期职业调查人员，并聘请新的研究人员和博士后学者。该项目被有效地设计为在两年的时间框架内完成，包括统计分析。 公共卫生相关性：这个项目意义重大，因为它通过使用一项受控良好的心理测量学研究，解决了复杂生活质量和神经认知评估工具，特别是神经生活质量和NIH工具箱神经认知组合方面的科学知识差距。Neuro-QOL和NIH工具箱将在一组患有和不患有抑郁症的帕金森病患者中使用，以优化他们在研究和临床领域的使用。此外，这个项目将辨别帕金森氏症或抑郁症状对生活质量和神经认知的影响。

DESCRIPTION (provided by applicant): This application addresses broad Challenge Area (05) Comparative Effectiveness Research and specific Challenge Topic, 05-NS-103: Validating NIH's New Clinical Tools in Populations with Neurological Disorders. The clinical impact of Parkinson's Disease (PD) and depression are well recognized and of considerable clinical significance, but less understood is their unique role and complex interaction in terms of quality of life and cognitive outcomes. As such, measurement of quality of life and neurocognitive function in patients with PD, particularly in the presence of comorbid depression, may have prognostic significance. Standard assessment tools have been used to evaluate quality of life and neurocognitive effects of PD and depression, but their use has been limited by poor psychometric properties and more importantly, lengthy administration time. To overcome these limitations, NIH developed two important tools, the Health-Related Quality of Life (Neuro-QOL) measure, and the NIH Toolbox Assessment of Neurological and Behavioral Function (NIH Toolbox). However, the Neuro-QOL and the NIH Toolbox have not been standardized in patients with Parkinson's disease. This research study Validating New NIH Clinical Tools in Parkinson's Disease with/without Depression will utilize the Neuro-QOL and the NIH Toolbox in a representative and well described cohort of 160 patients with Parkinson's disease (aim 1) and will discern the effects attributable to Parkinson's or depressive symptomatology (aim 2). This proposed project will advance NINDS' mission of developing new standardized tests as part of the NIH Blueprint for neuroscience, particularly quality of life and neurocognitive measures, in patients with Parkinson's disease and comorbid depression. Further, this project will address the American Recovery and Reinvestment Act goals of 1) infrastructure investment - through conducting multidisciplinary research to create a synergistic psychometric test development platform for present and future endeavors, and 2) job preservation and creation - by employing current faculty, early career investigators and hiring new research personnel and postdoctoral scholars. This project is efficiently designed to be completed, inclusive of statistical analyses, within a two-year time frame. PUBLIC HEALTH RELEVANCE: This project is significant as it addresses scientific knowledge gaps in sophisticated quality of life and neurocognitive assessment tools, specifically the Neuro-QOL and the NIH Toolbox neurocognitive battery, through the use of a well-controlled psychometric research study. The Neuro-QOL and NIH Toolbox will be administered in a cohort of patients with Parkinson's disease with and without depression to optimize their use in the research and clinical arenas. Further, this project will discern the quality of life and neurocognitive effects attributable to Parkinson's or depressive symptomatology.